Tesamorelin (INN) (trade name Egrifta) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy, approved initially in 2010. It is produced and developed by Theratechnologies, Inc. of Canada. The drug is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group.

Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection.

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that has been shown to increase growth hormone and IGF-1 levels. Tesamorelin is currently the most effective GH releasing hormone on the market. It is an injectable peptide that generates greater natural production of HGH (Human Growth Hormone). It binds and stimulates human GHRH receptors with similar potency as our own natural GHRH. It has not been shown to significantly affect other pituitary hormones in the body.

Gland Stimulated: Pituitary Gland

BENEFITS OF TESAMORELIN:

Increases natural productions of HGH (human growth hormone)

Increases IGF-1 (Insulin Growth Factor – 1) without altering glucose parameters

Reduced triglycerides

Reduced Visceral Adipose Tissue (VAT)

Reduced Carotid Intima Media Size (cIMT)

Improved cognition in adults over the age of 60.